TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00472056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m\^2 IV for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV x 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV x 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.
Study: NCT01395706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG Fluorescence technique
Description: This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated
Study: NCT03802513

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: Individualized physiotherapy including exercises to be performed by the Veteran at home.
Study: NCT04038034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10- MINIACTIVES
Description: COQUN oral formulation 100 mg BID

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02218671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WE 941 OD tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WE 941 OD tablets
Study: NCT01803789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Kirschner Wire
Study: NCT02739009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106 multiple ascending doses, intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple intravenous administrations
Study: NCT06497400

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian Jiu Jitsu
Description: Instruction of two classes each week for ten weeks of Brazilian Jiu Jitsu

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hatha Yoga
Description: Instruction of two classes each week for ten weeks of Hatha Yoga
Study: NCT01016652

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A Contact Lens
Description: standard sphere contact lens
Study: NCT06497400

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Participant will waitlist for 5 weeks and then be allowed to decide which intervention they want to do Group A/ Jiu Jitsu or Group B/Yoga for ten weeks..
Study: NCT03438123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CZT SPECT imaging
Description: Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
Study: NCT02202226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Study: NCT02202226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01981486

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: BID modified-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999 Tablets
Description: BID modified-release tablets (20 to 240 mg BID)
Study: NCT01674478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microlipid with fish oil
Description: Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
Study: NCT02333344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5mg
Description: two-year Zoledronic acid 5mg infusion treatment
Study: NCT00863356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2009-I-Epistaxis-1
Description: Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
Study: NCT04608370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active tPBM session
Description: In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham tPBM session
Description: In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
Study: NCT03847324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
Study: NCT01803789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Kirschner Wire
Study: NCT03027999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tight nursing follow-up
Description: In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~1. a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~2. A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP \> 2.7
Study: NCT03847324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physiotherapy
Description: This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
Study: NCT00847262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temisartan
Description: Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
Study: NCT02941302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detecting of Biological Borders of Gliomas
Description: Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
Study: NCT03252587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study: NCT00187122

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: See Detailed Description section for description of treatment plan.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: See Detailed Description section for description of treatment plan.
Study: NCT03252587

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT01674478

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microlipid
Description: A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
Study: NCT00511576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGCD0103 & Docetaxel
Description: In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGCD0103 & Docetaxel
Description: In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks.
Study: NCT01595295

Intervention type: OTHER
Intervention: non interventional
Study: NCT03905200

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D-speckle tracking imaging
Description: The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
Study: NCT05829161

Intervention type: BEHAVIORAL
Intervention: no intervention
Description: no intervention

Intervention type: BEHAVIORAL
Intervention: no intervention
Description: no intervention
Study: NCT02167074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25G FNA needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20G ProCore FNB needle
Study: NCT02540018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries
Description: Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter
Description: Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
Study: NCT03725683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Increased caliber balloon
Description: Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: matched caliber balloon
Description: Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events.
Study: NCT02942251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical features and medication
Description: This group will be suggested to take optimize treatment according to Chinese treatment guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-social
Description: This group will be suggested to add on psychotherapy on medical treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunology
Description: This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory abnormality
Description: This group will be suggested to more safety antidepressants.
Study: NCT02726451

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic Skin Care
Description: Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Skin Care
Description: Sensi Peel®, Rejuvenating Serum, and C\&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
Study: NCT02942251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comorbidity
Description: This group will be suggested to treat their comorbidities as well as treat MDD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
Study: NCT02232048

Intervention type: OTHER
Intervention: Transthoracic Echocardiogram
Study: NCT01312610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High flavanone orange juice
Description: High flavonone orange juice drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control orange juice
Description: Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
Study: NCT04748211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular Block
Description: USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalen Block
Description: USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
Study: NCT00827827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise- Strength Training
Description: 3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
Study: NCT05335980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nu-V3
Description: The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
Study: NCT01805466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVADO
Description: EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CPB
Description: conventional miniature cardiopulmonary bypass technique
Study: NCT02405546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Rotated (Group R)
Description: In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No pre-rotation
Description: ETT was not pre-rotated but rotated only if necessary
Study: NCT02910206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: etomidate is given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol is given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil is given intravenously
Study: NCT02530671

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing with manual toothbrush

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrushing with power toothbrush
Study: NCT04151082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04522323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: MEDI5752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: MEDI5752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: INLYTA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: INLYTA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: LENVIMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: LENVIMA
Study: NCT04531059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline,Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline,Metronidazole
Description: Antibiotics for H. pylori eradication
Study: NCT02910206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil is given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Cisatracurium is given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Cisatracurium is given intravenously
Study: NCT03511963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 100 mg in 4 ml Injection
Description: 7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin 100 mg in 4 ml Injection
Description: 7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
Study: NCT00589615

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary osteoporosis prevention educational program
Description: The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
Study: NCT01084876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P6
Description: Administered every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered every 3 weeks
Study: NCT02988973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA
Description: Subcutaneous administration